|Source:||The root barks of Periploca sepium Bunge|
|Biological Activity or Inhibitors:||1. Periplocin has anti-cancer effects on lung cancer cells, induces apoptosis and inhibits growth of cancer cells by the beta-catenin/Tcf signaling pathway.
2. Periplocin is used for treatment of rheumatoid arthritis, reinforcement of bones and tendons, palpitations or shortness of breath and lower extremity edema in traditional medicine.
3. Periplocin possesses potent immunoregulatory effect.
|Solvent:||DMSO, Pyridine, Methanol, Ethanol, etc.|
|Storage:||Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: email@example.com
|After receiving:||The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.|
|1 mg||5 mg||10 mg||20 mg||25 mg|
|1 mM||1.4351 mL||7.1755 mL||14.3509 mL||28.7018 mL||35.8773 mL|
|5 mM||0.287 mL||1.4351 mL||2.8702 mL||5.7404 mL||7.1755 mL|
|10 mM||0.1435 mL||0.7175 mL||1.4351 mL||2.8702 mL||3.5877 mL|
|50 mM||0.0287 mL||0.1435 mL||0.287 mL||0.574 mL||0.7175 mL|
|100 mM||0.0144 mL||0.0718 mL||0.1435 mL||0.287 mL||0.3588 mL|
Cell Physiol Biochem. 2014;33(3):859-68.
|Comparative proteomic analysis of anti-cancer mechanism by periplocin treatment in lung cancer cells.[Pubmed: 24685647]|
|Periplocin is used for treatment of rheumatoid arthritis, reinforcement of bones and tendons, palpitations or shortness of breath and lower extremity edema in traditional medicine. Our previous findings suggested that Periplocin could inhibit the growth of lung cancer both in vitro and in vivo. But the biological processes and molecular pathways by which Periplocin induces these beneficial effects remain largely undefined. METHODS: To explore the molecular mechanisms of Periplocin involved in anti-cancer activity, in the present study the protein profile changes of human lung cancer cell lines A549 in response to Periplocin treatment were investigated using the proteomics approaches (2-DE combined with MS/MS).Periplocin inhibited growth of lung cancer by down-regulating proteins, such as ATP5A1, EIF5A, ALDH1 and PSMB6. These findings may improve our understanding of the molecular mechanisms underlying the anti-cancer effects of Periplocin on lung cancer cells.|
Evid Based Complement Alternat Med. 2013;2013:958025.
|Antitumor Effect of Periplocin in TRAIL-Resistant Human Hepatocellular Carcinoma Cells through Downregulation of IAPs.[Pubmed: 23365613]|
|We extracted and purified cortex periplocae and identified Periplocin as the active ingredient that inhibited the growth of TNF-related apoptosis-inducing ligand-(TRAIL-) resistant hepatocellular carcinoma cells. The antitumor activity of Periplocin was further increased by TRAIL cotreatment. Periplocin sensitized TRAIL-resistant HCC through the following two mechanisms. First, Periplocin induced the expression of DR4 and FADD. Second, the cotreatment of TRAIL and Periplocin suppressed several inhibitors of apoptosis (IAPs). Both mechanisms resulted in the activation of caspase 3, 8, and 9 and led to cell apoptosis. In addition, intraperitoneal injection (IP) of Periplocin repressed the growth of hepatocellular carcinoma (HCC) in xenograft tumor model in mice. In summary, Periplocin sensitized TRAIL-resistant HCC cells to TRAIL treatment and resulted in tumor cell apoptosis and the repression of tumor growth in vivo.|
Cell Physiol Biochem. 2010;26(4-5):609-18.
|Periplocin inhibits growth of lung cancer in vitro and in vivo by blocking AKT/ERK signaling pathways.[Pubmed: 21063098 ]|
|We investigated the anti-tumor activity of Periplocin against lung cancer cells bothin vitro and in vivo, and explored its anti-cancer mechanism. Periplocin inhibited the growth of lung cancer cells and induced their apoptosis in time- and dose-dependent manners by cell cycle arrest in G0/G1 phase. Periplocin exhibited anti-tumor activity both in human (A549) and mouse (LL/2) lung cancer xenograft models. Immunohistochemical analysis revealed that intratumoral angiogenesis was significantly suppressed. Furthermore, anti-cancer activity mediated by Periplocin was associated with decreased level of phosphorylated AKT and ERK both in vitro and in vivo, which were important for cell growth and survival. Moreover, Periplocin induced apoptosis by downregulating Bcl-2 and upregulating Bax, leading to activation of caspase-3 and caspase-9. These findings suggested that Periplocin could inhibit the growth of lung cancer both in vitro and in vivo, which could be attributed to the inhibition of proliferation and the induction of apoptosis signaling pathway, such as AKT and ERK. These observations provide further evidence on the anti-tumor effect of Periplocin, and it may be of importance to further explore its potential role as a therapeutic agent for cancer.|
Oncol Rep. 2010 Aug;24(2):375-83.
|Periplocin from Cortex periplocae inhibits cell growth and down-regulates survivin and c-myc expression in colon cancer in vitro and in vivo via beta-catenin/TCF signaling.[Pubmed: 20596624]|
|In this study, human colon cancer SW480 cells were used to investigate the effect of CPP (Periplocin from Cortex periplocae) on the modulation of the beta-catenin/TCF signaling pathway. Our research results showed that Periplocin caused a dose- and time-dependent inhibition of cell growth as assessed by MTT assay and an induction in apoptosis as measured by flow cytometry and transmission electron microscopy. Furthermore, the Periplocin- treated cells were characterized by a decreased expression of beta-catenin protein in the total cell lysates and cytosolic and nuclear extracts. To determine the precise inhibitory mechanisms involved, further in-depth in vivo studies of Periplocin are warranted. In conclusion, our data suggest that Periplocin wields a multi-prong strategy to target the beta-catenin/Tcf signaling pathway, leading to the induction of apoptosis and inhibition of growth of colon cancer cells in vitro and in vivo. Therefore, Periplocin may become a potential agent against colon cancer.|
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2009 Oct;25(10):887-90.
|Immunoregulatory effects of periplocin from Cortex Periplocae in tumor-bearing mice.[Pubmed: 19811733]|
|To investigate the immune mechanisms for Periplocin from Cortex Periplocae (CPP) in tumor-bearing mice.CPP protected immune organs of tumor-bearing mice, increased obviously the percentage of CD4(+) and CD4(+)/CD8(+) among the T cell line, and enhanced lymphocyte proliferation of mice spleen significantly, stimulated the production of TNF-alpha, IL-2 and IL-12. The results suggested that CPP possessed potent immunoregulatory effect.|